Celcuity’s Earnings Call: Strong Data, Rising Cash Burn

Celcuity Inc. ((CELC)) has held its Q1 earnings call. Read on for the main highlights of the call.

Celcuity’s latest earnings call struck an optimistic clinical tone despite mounting financial pressures. Management highlighted robust Phase III results for breast cancer therapy gedatolisib, progress toward first‑line indications and a growing commercial infrastructure aimed at a multibillion‑dollar market. However, higher losses, rising cash burn and long timelines temper the near‑term outlook for investors.

Phase III Mutant Cohort Delivers Positive Top-Line Data

Gedatolisib’s triplet regimen with fulvestrant and palbociclib showed a statistically significant and clinically meaningful boost in progression‑free survival versus alpelisib plus fulvestrant in PIK3CA‑mutant patients. The doublet of gedatolisib plus fulvestrant also improved progression‑free survival, and both regimens were generally well tolerated with no new safety signals, with detailed data heading to ASCO in June.

Wild-Type Results Set New Efficacy Benchmarks

Previously reported VIKTORIA‑1 wild‑type data set a high bar, with the gedatolisib triplet delivering a 7.3‑month incremental gain in median progression‑free survival over fulvestrant, noted as exceeding prior Phase III results in this setting. The triplet also achieved a 17.5‑month median duration of response and a 31‑point increase in objective response rate versus control, alongside low discontinuation rates and rapid improvement in stomatitis.

First-Line VIKTORIA-2 Expansion Targets Larger Population

Celcuity has amended VIKTORIA‑2 to cover both endocrine‑resistant and endocrine‑sensitive HR‑positive, HER2‑negative breast cancer, shrinking Study 1’s sample size to 440 while maintaining statistical power. Study 2 will enroll about 740 endocrine‑sensitive patients, but top‑line data are not expected until 2028 for Study 1 and 2030 for Study 2, underscoring the long road to first‑line approval.

Subcutaneous Gedatolisib Aims to Support Long-Term Use

The company is advancing a subcutaneous formulation of gedatolisib designed for chronic treatment, filing its first U.S. patent on an injectable version and optimizing candidates through stability and animal studies. Management’s goal is to match the efficacy of the IV formulation while keeping injection volumes practical, though regulatory expectations for pharmacokinetic and clinical equivalence could add time and cost.

Prostate Cancer Combo Shows Early Promise

In metastatic castration‑resistant prostate cancer, a Phase Ib study of gedatolisib plus darolutamide produced a 6‑month radiographic progression‑free survival rate of 67%, compared with historical rates around 40%. Median radiographic progression‑free survival reached 9.1 months, and the combination was generally well tolerated with no dose‑limiting toxicities or treatment discontinuations driven by side effects.

Commercial Engine Built Ahead of Potential Launch

Celcuity has largely completed its commercial build‑out, with oncology sales specialists now fully hired and averaging 24 years in pharma and 16 in oncology. The company is actively engaging payers and key accounts, positioning gedatolisib for a U.S. second‑line HR‑positive, HER2‑negative breast cancer market it pegs at more than $5 billion annually, with management eyeing potential peak second‑line revenue up to $2.5 billion.

Cash Runway Extends Through 2027 With Debt Support

The company ended March 31, 2026 with $387.1 million in cash, cash equivalents and short‑term investments, which together with its debt facility is expected to fund operations through 2027. That runway should carry Celcuity through the upcoming regulatory decision and early commercialization efforts, but reliance on debt drawdowns underscores the need for disciplined capital allocation as expenses rise.

Losses Widen as Operating Scale-Up Accelerates

Celcuity’s GAAP net loss grew to $52.8 million, or $0.97 per share, from $37.0 million, or $0.86, a year ago, reflecting roughly 43% deterioration. On a non‑GAAP basis, adjusted net loss reached $46.8 million, or $0.86 per share, versus $34.7 million, or $0.81, highlighting the financial drag of an expanding development and commercial program.

Cash Burn and SG&A Surge on Launch Preparation

Net cash used in operating activities jumped to $55.1 million from $35.9 million, a roughly 54% increase that heightens near‑term financing needs. Selling, general and administrative expenses climbed to $17.4 million from $6.3 million, up about 176%, largely due to commercial hiring and launch‑related activities that lift fixed costs ahead of any product revenues.

Shifting R&D Mix and Manufacturing Spend

Research and development expenses rose to $33.1 million from $29.8 million, driven by higher personnel and consulting costs and a $5.4 million increase in manufacturing and other expenses. These outlays were partly offset by a $5.1 million decline in clinical trial spending as VIKTORIA‑1 costs receded, signaling a gradual transition from late‑stage trial execution toward manufacturing and lifecycle planning.

Regulatory Timelines and Safety Watchpoints

Investors face meaningful timing uncertainty, with a key regulatory decision still pending and first‑line VIKTORIA‑2 data years away, while a subcutaneous formulation will likely require additional bridging studies. Stomatitis remains an adverse event to monitor despite low treatment discontinuation rates and relatively quick resolution in trials, as real‑world tolerability could influence uptake and adherence.

Guidance Highlights: PDUFA Decision and Long-Term Horizon

Management reiterated that the priority review decision date for gedatolisib remains scheduled for July 17, 2026 and indicated plans to seek a supplemental filing if approved, while confirming that current cash plus debt capacity should fund operations through 2027. They emphasized the large addressable population in both second‑line and future first‑line settings, but also signaled that full realization of gedatolisib’s potential will extend well into the next decade.

Celcuity’s call painted the picture of a company with a potentially best‑in‑class breast cancer therapy and a ready‑to‑go commercial team, balanced against sizeable losses, rising cash usage and a lengthy development path. For investors, the story hinges on the upcoming regulatory decision and the company’s ability to convert strong clinical signals into durable commercial traction without overextending its balance sheet.